Pegvaliase

Pegvaliase

Clinical data
Pronunciation	peg val' i ase
Trade names	Palynziq
Other names	Pegvaliase-pqpz; PEG-PAL; RAvPAL-PEG
AHFS/Drugs.com	Monograph
MedlinePlus	a618057
License data	US DailyMed: Pegvaliase
Pregnancy category	AU: D
Routes of administration	Subcutaneous
ATC code	A16AB19 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only / Schedule D US: ℞-only EU: Rx-only
Identifiers
IUPAC name (2S)-2-amino-6-[6-(2-methoxyethoxy)hexanamido]hexanoic acid
CAS Number	1585984-95-7
PubChem CID	86278362
DrugBank	DB12839
ChemSpider	58172730
UNII	N6UAH27EUV
KEGG	D11077
Chemical and physical data
Formula	C15H30N2O5
Molar mass	318.414 g·mol−1
3D model (JSmol)	Interactive image
SMILES COCCOCCCCCC(=O)NCCCC[C@H](N)C(O)=O
InChI InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1 Key:NPOCDVAOUKODSQ-ZDUSSCGKSA-N

Pegvaliase, sold under the brand name Palynziq, is a medication for the treatment of the genetic disease phenylketonuria. Chemically, it is a pegylated derivative of the enzyme phenylalanine ammonia-lyase that metabolizes phenylalanine to reduce its blood levels.

It was approved by the Food and Drug Administration for use in the United States in 2018. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.

External links

• "Pegvaliase". Drug Information Portal. U.S. National Library of Medicine.